TY - JOUR
TI - No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(Immuno)therapy
AU - Baliakas, P.
AU - Mattsson, M.
AU - Hadzidimitriou, A.
AU - Minga, E.
AU - Agathangelidis, A.
AU - Sutton, L.-A.
AU - Scarfo, L.
AU - Davis, Z.
AU - Yan, X.-J.
AU - Plevova, K.
AU - Sandberg, Y.
AU - Vojdeman, F.J.
AU - Tzenou, T.
AU - Chu, C.C.
AU - Veronese, S.
AU - Mansouri, L.
AU - Smedby, K.E.
AU - Giudicelli, V.
AU - Nguyen-Khac, F.
AU - Panagiotidis, P.
AU - Juliusson, G.
AU - Anagnostopoulos, A.
AU - Lefranc, M.-P.
AU - Trentin, L.
AU - Catherwood, M.
AU - Montillo, M.
AU - Niemann, C.U.
AU - Langerak, A.W.
AU - Pospisilova, S.
AU - Stavroyianni, N.
AU - Chiorazzi, N.
AU - Oscier, D.
AU - Jelinek, D.F.
AU - Shanafelt, T.
AU - Darzentas, N.
AU - Belessi, C.
AU - Davi, F.
AU - Ghia, P.
AU - Rosenquist, R.
AU - Stamatopoulos, K.
JO - Haematologica-the hematology journal
PY - 2018
VL - 103
TODO - 4
SP - e158-e161
PB - Ferrata Storti Foundation
SN - null
TODO - 10.3324/haematol.2017.182634
TODO - cyclophosphamide;  fludarabine;  rituximab, adult;  aged;  cancer chemotherapy;  cancer immunotherapy;  chronic lymphatic leukemia;  female;  follow up;  gene deletion;  gene expression;  gene mutation;  human;  immunogenetics;  Letter;  long term survival;  major clinical study;  male;  retrospective study;  chronic lymphatic leukemia;  drug therapy;  immunotherapy;  middle aged;  mortality;  survival rate;  very elderly;  young adult, Adult;  Aged;  Aged, 80 and over;  Drug Therapy;  Female;  Humans;  Immunotherapy;  Leukemia, Lymphocytic, Chronic, B-Cell;  Male;  Middle Aged;  Retrospective Studies;  Survival Rate;  Young Adult
TODO - null
ER -